To progress, life science companies require investment,
developmental partners, and clear engagement with the research and medical communities.
80th Atom is a consultancy that develops bespoke life science communications programmes supporting its clients to access capital, establish and progress relationships with commercial partners, gain access to and influence KOLs, all through building and presenting a strong, credible, corporate and scientific rationale.
Adam Michael, founder of 80th Atom, has 25 years' experience in the sector covering drug development, medtech, and diagnostics, from academic spin-outs to multinational corporations. He has operated in multiple roles within the industry including the media and publishing, finance, business development, KOL engagement and patient recruitment.
A broad commercial and scientific understanding of the sector enables 80th Atom to anticipate its clients' near and long-term communications requirements, provide strategic access to the full-scope of communications channels, and support the delivery of corporate objectives and the corresponding valuation.
80th Atom creates bespoke communications programmes that take advantage of 25 years experience and knowledge of what:
investors seek in a company;
potential partners require in an asset; and why
researchers adopt new technologies; and
medical practitioners need better therapy for their patients.
Our programmes start with a strong corporate story and scientific rationale, which are conveyed to these specific audiences through the full suite of communication tools and channels, to support commercial success through delivery of new healthcare technologies, to the benefit of patients.
80th Atom programmes encompass:
Corporate positioning and messaging
B2B communications / business development
Financial PR and investor relations
News releases / company announcements
Online and digital communications
Crisis and issues management
Brand and identity creation
There always have been and will be technologies that reshape and develop our global society for the better. Over the past three decades, the expansion of scientific knowledge that underpins the life sciences has generated revolutionary technologies and entirely new therapeutic approaches. Such intelligence means that the extension of healthy, active, and contributory life expectancy to 120 is becoming a reality.
80th Atom seeks to introduce and explain such technologies and therapeutics to the life science and healthcare communities; to advocate for the businesses and their products, grow public interest and knowledge, and support those products through to commercial and societal success.